Search

Your search keyword '"Kruyt, Frank A.E."' showing total 149 results
Start Over Author "Kruyt, Frank A.E."
149 results on '"Kruyt, Frank A.E."'

4. Fluorescence guided surgery for the detection of meningioma using bevacizumab-IRDye800CW (LUMINA trial) - a single center phase I/II study

Author

Dijkstra, Bianca, primary, Cordia, Quirine C.F., additional, Nonnekens, Julie, additional, Meersma, Gert Jan, additional, Donthu, Venkata S., additional, Wagemakers, Michiel, additional, Vergeer, Rob A., additional, Rijtema, Gijs, additional, Nagengast, Wouter, additional, Kruijff, Schelto, additional, den Dunnen, Wilfred F.A., additional, Kruyt, Frank A.E., additional, and Groen, Rob J.M., additional

Published
2023
Full Text
View/download PDF

10. BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity

Author

Ferreira, Adilson Kleber, Pasqualoto, Kerly Fernanda Mesquita, Kruyt, Frank A.E., Palace-Berl, Fanny, Azevedo, Ricardo Alexandre, Turra, Kely Medeiros, Rodrigues, Cecilia Pessoa, Ferreira, Ana Carolina Franco, Salomón, Maria Alejandra Clavijo, de Sá, Paulo Luiz, Junior, Farias, Camyla Fernandes, Figueiredo, Carlos Rogerio, Tavares, Leoberto Costa, Barbuto, José Alexandre Marzagão, and Jorge, Salomão Dória

Published
2016
Full Text
View/download PDF

11. Correction to: Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma (Journal of Neuro-Oncology, (2021), 153, 2, (211-222), 10.1007/s11060-021-03739-1)

Author

Dijkstra, Bianca M., de Jong, Marion, Stroet, Marcus C.M., Andreae, Fritz, Dulfer, Sebastiaan E., Everts, Marieke, Kruijff, Schelto, Nonnekens, Julie, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., Groen, Rob J.M., Radiology & Nuclear Medicine, and Molecular Genetics

Subjects
SDG 3 - Good Health and Well-being
Abstract

The Funding section in the initial online article was incomplete. The original article has been corrected.

Published
2021

14. Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate:a consequence from cyanine-labeling of small molecules

Author

Stroet, Marcus C.M., Dijkstra, Bianca M., Dulfer, Sebastiaan E., Kruijff, Schelto, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., Groen, Rob J.M., Seimbille, Yann, Panth, Kranthi M., Mezzanotte, Laura, Lowik, Clemens W.G.M., de Jong, Marion, Stroet, Marcus C.M., Dijkstra, Bianca M., Dulfer, Sebastiaan E., Kruijff, Schelto, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., Groen, Rob J.M., Seimbille, Yann, Panth, Kranthi M., Mezzanotte, Laura, Lowik, Clemens W.G.M., and de Jong, Marion

Abstract

Background: There is a growing body of nuclear contrast agents that are repurposed for fluorescence-guided surgery. New contrast agents are obtained by substituting the radioactive tag with, or adding a fluorescent cyanine to the molecular structure of antibodies or peptides. This enables intra-operative fluorescent detection of cancerous tissue, leading to more complete tumor resection. However, these fluorescent cyanines can have a remarkable influence on pharmacokinetics and tumor uptake, especially when labeled to smaller targeting vectors such as peptides. Here we demonstrate the effect of cyanine-mediated dead cell-binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate (800CW-TATE) and how this can be used as an advantage for fluorescence-guided surgery. Results: Binding of 800CW-TATE could be blocked with DOTA0-Tyr3-octreotate (DOTA-TATE) on cultured SSTR2-positive U2OS cells and was absent in SSTR2 negative U2OS cells. However, strong binding was observed to dead cells, which could not be blocked with DOTA-TATE and was also present in dead SSTR2 negative cells. No SSTR2-mediated binding was observed in frozen tumor sections, possibly due to disruption of the cells in the process of sectioning the tissue before exposure to the contrast agent. DOTA-TATE blocking resulted in an incomplete reduction of 61.5 ± 5.8% fluorescence uptake by NCI-H69-tumors in mice. Near-infrared imaging and dead cell staining on paraffin sections from resected tumors revealed that fluorescence uptake persisted in necrotic regions upon blocking with DOTA-TATE. Conclusion: This study shows that labeling peptides with cyanines can result in dead cell binding. This does not hamper the ultimate purpose of fluorescence-guided surgery, as necrotic tissue appears in most solid tumors. Hence, the necrosis binding can increase the overall tumor uptake. Moreover, necro

Published
2021

15. Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma

Author

Dijkstra, Bianca M., de Jong, Marion, Stroet, Marcus C.M., Andreae, Fritz, Dulfer, Sebastiaan E., Everts, Marieke, Kruijff, Schelto, Nonnekens, Julie, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., Groen, Rob J.M., Dijkstra, Bianca M., de Jong, Marion, Stroet, Marcus C.M., Andreae, Fritz, Dulfer, Sebastiaan E., Everts, Marieke, Kruijff, Schelto, Nonnekens, Julie, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., and Groen, Rob J.M.

Abstract

Purpose: Meningioma recurrence rates can be reduced by optimizing surgical resection with the use of intraoperative molecular fluorescence guided surgery (MFGS). We evaluated the potential of the fluorescent tracer 800CW-TATE for MFGS using in vitro and in vivo models. It targets somatostatin receptor subtype 2 (SSTR2), which is overexpressed in all meningiomas. Methods: Binding affinity of 800CW-TATE was evaluated using [177Lu] Lu-DOTA-Tyr3-octreotate displacement assays. Tumor uptake was determined by injecting 800CW-TATE in (SSTR2-positive) NCI-H69 or (SSTR2-negative) CH-157MN xenograft bearing mice and FMT2500 imaging. SSTR2-specific binding was measured by comparing tumor uptake in NCI-H69 and CH-157MN xenografts, blocking experiments and non-targeted IRDye800CW-carboxylate binding. Tracer distribution was analyzed ex vivo, and the tumor-to-background ratio (TBR) was calculated. SSTR2 expression was determined by immunohistochemistry (IHC). Lastly, 800CW-TATE was incubated on frozen and fresh meningioma specimens and analyzed by microscopy. Results: 800CW-TATE binding affinity assays showed an IC50 value of 72 nM. NCI-H69 xenografted mice showed a TBR of 21.1. 800CW-TATE detection was reduced after co-administration of non-fluorescent DOTA-Tyr3-octreotate or administration of IRDye800CW. CH-157MN had no tumor specific tracer staining due to absence of SSTR2 expression, thereby serving as a negative control. The tracer bound specifically to SSTR2-positive meningioma tissues representing all WHO grades. Conclusion: 800CW-TATE demonstrated sufficient binding affinity, specific SSTR2-mediated tumor uptake, a favorable biodistribution, and high TBR. These features make this tracer very promising for use in MFGS and could potentially aid in safer and a more complete meningioma resection, especially in high-grade meningiomas or those a

Published
2021

16. Correction to:Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma (Journal of Neuro-Oncology, (2021), 153, 2, (211-222), 10.1007/s11060-021-03739-1)

Author

Dijkstra, Bianca M., de Jong, Marion, Stroet, Marcus C.M., Andreae, Fritz, Dulfer, Sebastiaan E., Everts, Marieke, Kruijff, Schelto, Nonnekens, Julie, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., Groen, Rob J.M., Dijkstra, Bianca M., de Jong, Marion, Stroet, Marcus C.M., Andreae, Fritz, Dulfer, Sebastiaan E., Everts, Marieke, Kruijff, Schelto, Nonnekens, Julie, den Dunnen, Wilfred F.A., Kruyt, Frank A.E., and Groen, Rob J.M.

Abstract

The Funding section in the initial online article was incomplete. The original article has been corrected.

Published
2021

20. Necrosis Binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: Pros and Cons of Using Cyanine-labeled Small Molecules

Author

Stroet, Marcus Cornelis Maria, primary, Dijkstra, Bianca M., additional, Dulfer, Sebastiaan E., additional, Kruijff, Schelto, additional, Dunnen, Wilfred F.A. den, additional, Kruyt, Frank A.E., additional, Groen, Rob J.M., additional, Seimbille, Yann, additional, Panth, Kranthi M., additional, Mezzanotte, Laura, additional, Lowik, Clemens W.G.M., additional, and Jong, Marion de, additional

Published
2021
Full Text
View/download PDF

25. A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA

Author

Waisfisz, Quinten, De Winter, Johan P., Kruyt, Frank A.E., De Groot, Jan, Van der Weel, Laura, Dijkmans, Lonneke M., Zhi, Yu, Arwert, Fre, Scheper, Rik J., and Youssofian, Hagop

Subjects
Fanconi's anemia -- Genetic aspects, Phenotype -- Research, Proteins -- Research, Science and technology
Abstract

Fanconi anemia (FA) is a recessively inherited disease characterized at the cellular level by spontaneous chromosomal instability and specific hypersensitivity to cross-linking agents. FA is genetically heterogeneous, comprising at least eight complementation groups (A-H). We report that the protein encoded by the gene mutated in complementation group G (FANCG) localizes to the cytoplasm and nucleus of the cell and assembles in a molecular complex with the FANCA protein, both in vivo and in vitro. Endogenous FANCA/FANCG complex was detected in both non-FA cells and in FA cells from groups D and E. By contrast, no complex was detected in specific cell lines belonging to groups A and G, whereas reduced levels were found in cells from groups B, C, F, and H. Wild-type levels of FANCA/FANCG complex were restored upon correction of the cellular phenotype by transfection or cell fusion experiments, suggesting that this complex is of functional significance in the FA pathway. These results indicate that the cellular FA phenotype can be connected to three biochemical subtypes based on the levels of FANCA/FANCG complex. Disruption of the complex may provide an experimental strategy for chemosensitization of neoplastic cells.

Published
1999

36. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma

Author

Zomerman, Walderik W., primary, Plasschaert, Sabine L.A., additional, Conroy, Siobhan, additional, Scherpen, Frank J., additional, Meeuwsen-de Boer, Tiny G.J., additional, Lourens, Harm J., additional, Guerrero Llobet, Sergi, additional, Smit, Marlinde J., additional, Slagter-Menkema, Lorian, additional, Seitz, Annika, additional, Gidding, Corrie E.M., additional, Hulleman, Esther, additional, Wesseling, Pieter, additional, Meijer, Lisethe, additional, van Kempen, Leon C., additional, van den Berg, Anke, additional, Warmerdam, Daniël O., additional, Kruyt, Frank A.E., additional, Foijer, Floris, additional, van Vugt, Marcel A.T.M., additional, den Dunnen, Wilfred F.A., additional, Hoving, Eelco W., additional, Guryev, Victor, additional, de Bont, Eveline S.J.M., additional, and Bruggeman, Sophia W.M., additional

Published
2018
Full Text
View/download PDF

40. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy

Author

Honing, Judith, primary, Pavlov, Kirill V., additional, Mul, Véronique E.M., additional, Karrenbeld, Arend, additional, Meijer, Coby, additional, Faiz, Zohra, additional, Smit, Justin K., additional, Hospers, Geke A.P., additional, Burgerhof, Johannes G.M., additional, Kruyt, Frank A.E., additional, Kleibeuker, Jan H., additional, and Plukker, John T.M., additional

Published
2015
Full Text
View/download PDF

41. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET

Author

den Hollander, Martha W., primary, Bensch, Frederike, additional, Glaudemans, Andor W.J.M., additional, Oude Munnink, Thijs H., additional, Enting, Roelien H., additional, den Dunnen, Wilfred F.A., additional, Heesters, Mart A.A.M., additional, Kruyt, Frank A.E., additional, Lub-de Hooge, Marjolijn N., additional, Cees de Groot, Jan, additional, Pearlberg, Joseph, additional, Gietema, Jourik A., additional, de Vries, Elisabeth G.E., additional, and Walenkamp, Annemiek M.E., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results